Core Viewpoint - The company Fulejia experienced a decline in stock price and trading volume, with significant changes in financing and shareholding structure, indicating potential challenges in revenue and profit generation [1][2][3]. Financing and Trading Activity - On November 20, Fulejia's stock dropped by 4.58%, with a trading volume of 234 million yuan. The financing buy-in amounted to 28.92 million yuan, while financing repayment was 26.48 million yuan, resulting in a net financing buy of 2.44 million yuan. The total financing and margin balance reached 116 million yuan [1]. - The current financing balance of 115 million yuan represents 5.34% of the circulating market value, which is below the 30th percentile level over the past year, indicating a low financing level [1]. - In terms of margin trading, Fulejia repaid 100 shares and sold 500 shares on November 20, with a selling amount of 13,400 yuan. The margin balance stood at 458,600 yuan, exceeding the 80th percentile level over the past year, indicating a high margin level [1]. Company Performance - For the period from January to September 2025, Fulejia reported a revenue of 1.297 billion yuan, a year-on-year decrease of 11.54%. The net profit attributable to shareholders was 325 million yuan, down 36.73% year-on-year [2]. - Since its A-share listing, Fulejia has distributed a total of 1 billion yuan in dividends [3]. Shareholding Structure - As of November 10, Fulejia had 14,900 shareholders, an increase of 0.69% from the previous period. The average number of circulating shares per shareholder decreased by 0.68% to 5,192 shares [2]. - Among the top ten circulating shareholders, notable changes include a decrease in holdings by major ETFs, with Huabao Zhongzheng Medical ETF reducing its stake by 317,500 shares, and new entry by Hong Kong Central Clearing Limited holding 462,800 shares [3].
敷尔佳11月20日获融资买入2891.84万元，融资余额1.15亿元